Biodel , U.S. Patent Covering Lead Product Candidates VIAject(TM) and VIAtab(TM)

Sept 27, 2007 - Biodel Inc. (Nasdaq: BIOD) announced the receipt of a notice of issuance from the United States Patent and Trademark Office (USPTO) for the Company's patent encompassing VIAject(TM) and VIAtab(TM), Biodel's two product candidates in clinical trials...
...VIAject(TM) is a rapid-acting injectable human insulin intended for meal- time use by patients with Type 1 or Type 2 diabetes...VIAtab(TM) is a sublingual tablet formulation of insulin... Biodel's Press Release -

Biodel has expanded its two ongoing pivotal Phase III clinical trials of VIAject(TM) into Europe

Sept 21, 2007- Biodel Inc. (Nasdaq: BIOD) today announced that the Company has expanded its two ongoing pivotal Phase III clinical trials of VIAject(TM) into Europe. Clinical sites have been initiated in Germany and patient treatment has begun...The two studies, one enrolling 400 Type 1 diabetic patients and the other enrolling 400 Type 2 diabetic patients.. Biodel's Press Release -

Biodel , VIAject(TM) Phase II Meal Study Data

Sept 18, 2007- Biodel Inc. (Nasdaq: BIOD) announced additional clinical data from its VIAject(TM) program at the 43rd Scientific Sessions of the European Association for the Study of Diabetes (EASD).
VIAject(TM) Phase II meal study data was disclosed in an oral presentation at EASD entitled, "Pharmacokinetics and pharmacodynamics of insulin VIAject(TM), lispro and regular human insulin when injected subcutaneously immediately before a meal in patients with Type 1 diabetes."... Biodel's Press release -